A weight-loss jab loved by celebs may not be a miracle fix – as experts warn users are likely to pile pounds back on after they stop taking the recently approved drug.
Semaglutide, sold under the brand name Wegovy and given as a weekly injection, has been given the green light by watchdog NICE to be used by the NHS.
The drug, which can only be taken for a maximum of two years, was described as the ‘most powerful pharmaceutical tool to date’, by one expert.
But Professor Jason Halford, from the School of Psychology at the University of Leeds, warned users will see rapid weight gain once they have completed their treatment.
The jab, which costs £73 a month, works by hijacking the brain to suppress appetite and reduce calorie intake, resulting in substantial weight loss.
Alex Guevara, 46, (pictured) is a paramedic practitioner from Milton Keynes. He has three children, and lives with his wife Christina, 29. He said: ‘When a friend told me about semaglutide I felt I had nothing to lose. I went to a private clinic, and paid £250 a month for six months’
Trials found those on it lost around 12 per cent of their body weight – and slashed their risk of developing type 2 diabetes by more than half.
The NICE approval means patients could be referred for the DIY jabs instead of gastric band or other weight loss surgery, reducing the burden on hospitals and saving the NHS millions.
Professor Halford told BBC Radio 4: ‘I think it’s one of the most powerful pharmaceutical tool to date that we’ve had access to.’
However, he said that the drug needs to be taken in the context of specialist weight management services, which he claimed there are not enough of in the UK, making the treatment hard for many to access.
Professor Halford said the drug works by signalling satiety to the brain and suppressing appetite, so once a person stops taking the drug, the weight is likely to return.
‘What we know when you come off the drug at two years you see rapid weight gain because you’ve no longer got that drug-suppressing appetite systems,’ he said.
But Professor Halford added that once data of the drug’s longer-term effects is available, providing it is deemed safe, it may be used for a much longer period by people who struggle to keep weight off.
Experts welcomed Wegovy’s recommendation for those with a Body Mass Index (BMI) of 30 and above, as part of a weight-loss programme of diet and exercise.
Tam Fry, from the National Obesity Forum, said this is ‘the weight-loss drug that we’ve been waiting for’ and urged health leaders to ration supplies to those in greatest need.
He said: ‘It’s a game-changer and so successful that Hollywood A-listers are now using it to slim and show off their figures.
‘The real danger is that there may not be enough to go round in the short-term.
‘You should not be using it just to lose a few pounds because that might will jeopardise the health of those who really need it, those who have diabetes Type 2 and morbid obesity.’
The drug has been hailed a miracle cure by some who have taken it.
Semaglutide, marketed as Wegovy, will be available in pharmacies from the spring
Ana McKenna (pictured before and after the drug) told DailyMail.com she plans to stop using Wegovy after reaching her weight loss target
Ms Rice (pictured) lost 50 pounds on Wegovy after using it for the last six months
Alex Guevara, 46, is a paramedic practitioner from Milton Keynes. He has two children from his first marriage, and a third with wife Christina, 29, who’s also a paramedic.
He said by April last year he was touching 20st and his weight left him feeling suicidal.
Mr Guevara started on semaglutide and within a few days said he started feeling less hungry and felt much happier.
‘I needed something dramatic to break the cycle and stop me hurtling towards Type 2 diabetes, cardiovascular diseases and stroke,’ he added. ‘Semaglutide should be available to anyone who needs it.’
Made by Novo Nordisk, it is hoped the jabs – which will initially help around 35,000 people a year – will be available to patients within weeks as part of NHS specialist weight management services.
Wegovy works by triggering the body to produce a hormone called glucagon-like peptide-1 that is released naturally from the intestines after meals
A UK study found that people who used Wegovy experienced rapid weight loss, dropping 18% of their weight over 68 weeks. They regained two-thirds of that weight, or 12% of their original body weight in the year after dropping the weekly injections. Experts says the drug needs to be used over a lifetime to keep off the pounds
Top Gear host Jeremy Clarkson (left) revealed he was taking Ozempic, a brand of semaglutide, in a bid to lose weight. When asked in October whether following a healthier diet or hitting the gym was behind his 30lb (13.6kg) weight loss, Elon Musk (right) credited ‘fasting’ and ‘Wegovy’
Elon Musk (left) credits his spectacular weight loss in 2020 to Wegovy. The tech tycoon looked noticeably slim when he first arrived in Twitter HQ after purchasing the company in October (right)
Kim Kardashian is rumoured to have used Wegovy to rapidly lose weight in order to fit in Marilyn Monroe’s famous ‘Happy Birthday Mr President’ dress at the 2022 Met Gala (pictured)
The drugs work by suppressing appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating, making people feel so they eat less and lose weight.
Adults with a BMI classed as obese and at least one weight-related illness such as pre-diabetes, Type 2 diabetes, high blood pressure, cardiovascular disease or high blood pressure, could qualify.
The jabs are self-administered by patients once a week using pre-filled pens, for a minimum of 16 weeks.
They can initially be placed on the drug for a maximum of two years, although regulators say there is scope to increase this if real-world data shows it continues to be an effective weight loss tool.
Around 19million people in England are obese, which costs the NHS more than £6billion a year.
Trials found patients given the weekly jab lost a tenth of their body weight in just 20 weeks – 25 times more than those on a placebo – consuming around 35 per cent fewer calories.
Overweight and obese participants given regular doses also saw their odds of suffering Type 2 diabetes fall by up to 61 per cent.
Obesity expert Alex Miras, a professor of endocrinology at Ulster University, said it will make a massive difference to people living with obesity.
‘This decision made by NICE is a pivotal moment for the treatment of people living with obesity,’ he said, adding: ‘The weight loss that can be achieved with this safe medication is substantial and likely to lead to the improvement of obesity related complications in a large number of patients.’
The drug is already prescribed at much lower doses to treat patients with Type 2 diabetes, under the brand name Ozempic.
It has led celebrities Elon Musk and Jeremy Clarkson to both publicly credit it with helping them to shift the pounds.
Meanwhile, Kim Kardashian was rumoured to have used it to rapidly lose 16lbs (7.3kg) to fit into Marilyn Monroe’s iconic ‘Happy Birthday Mr President’ dress at the 2022 Met Gala.
However, it is not without side effects with users commonly complaining of nausea, constipation and diarrhoea after taking the medication.
It has also been known to make food less appealing, potentially ruining the enjoyment of eating altogether.
Helen Knight, director of medicines evaluation at NICE, said: ‘For some people losing weight is a real challenge which is why a medicine like semaglutide is a welcome option.’
Dietitian Dr Duane Mellor, of Aston Medical School, Aston University, said: ‘It is important to remember that semaglutide works alongside and supports healthy lifestyle changes and when people are being offered semaglutide they are also given ongoing support to make changes and maintain these changes with respect to diet and lifestyle.
‘As all individuals initially being offered semaglutide via the NHS will be supported by specialist weight management services this should including support from a specialist dietitian.’